Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
Refractory Ewing SarcomaRelapsed Ewing SarcomaEwing Sarcoma
Interventions
DRUG

Lurbinectedin

Administered as intravenous (IV) infusion once every 3 weeks (Q3W)

Trial Locations (15)

10065

RECRUITING

Memorial Sloan Kettering, New York

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20010

RECRUITING

Childrens National Hospital Michigan, Washington D.C.

21238

RECRUITING

Johns Hopkins University, Baltimore

30329

RECRUITING

Arthur M. Blank Hospital Children's Healthcare of Atlanta, Atlanta

33701

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

43205

RECRUITING

Nationwide Childrens, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

49503

RECRUITING

Corewell Health, Grand Rapids

75390

RECRUITING

UT Southwestern in Texas, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

94304

RECRUITING

Stanford Children's Health, Palo Alto

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY